Rayner manufactured the world’s first IOL in 1949, and has remained at the forefront of innovation for 70 years, focused on providing you and your patients with the best IOLs and opthalmic solutions – always driven by science to improve patient outcomes and safety.
Rayner is the only manufacturer of IOLs in the UK, with its state-of-the-art manufacturing plant and Global Headquarters on the South Coast of England.
New York, USA, March 26, 2021 – RayOne EMV, a new fully preloaded non-diffractive IOL by Rayner, has received FDA approval.
RayOne EMV was developed in collaboration with world renowned surgeon Professor Graham Barrett, president of the Australasian Society of Cataract & Refractive Surgeons.
“I collaborated with Rayner on bringing to market RayOne EMV, an exciting new product for all surgeons,” said Professor Barrett.
Dr. Mariano Royo, Director of Ophthalmology at the Hospital San Rafael in Madrid and Director of the Ophthalmic Institute of Madrid, shared his clinical results of 22 eyes of 11 patients implanted with RayOne EMV measured at six months post-op.
Dr. Royo reported that 100% of his patients that received RayOne EMV achieved spectacle independence in the distance and intermediate range.
The average reading aid at 33 cm was reported to be +1.5 D, and one in three patients had functional near vision without the need for spectacles.
RayOne EMV is a cost-effective solution for patients when diffractive IOLs may be cost prohibitive or if there are concerns about dysphotopsia.
“Following approval of our RayOne and RayPRO platforms in 2019 we have been steadily increasing our investment in the USA to be one of our most important markets worldwide. The approval of RayOne EMV is important as it allows surgeons to offer patients a new option which has been tried and tested in thousands of patients around the world” stated Tim Clover, Rayner CEO.
Patient outcomes for RayOne EMV can be tracked using RayPRO, a free contactless telehealth solution that collects three years’ worth of Patient Reported Outcomes after cataract or refractive surgery.
Rayner designs and manufactures Intraocular Lenses (IOLs) as well as other ophthalmic solutions for use across the cataract patient’s clinical pathway.
In partnership with Sir Harold Ridley, Rayner manufactured the world’s first intraocular lens, which was implanted in a patient on the 29th November 1949 in the St. Thomas Hospital in London, United Kingdom.
With over 70 years of continuous growth and experience, we remain at the forefront of innovation. We are focused on providing the best visual outcomes for clinicians and patients and are driven by science to improve performance and safety.
In 2020 Rayner won the Queen’s Award for Enterprise in the category Innovation for its RayOne preloaded injector.
Headquartered in Worthing, United Kingdom, Rayner markets its products worldwide in over 90 countries through a network of distributors as well as direct sales offices in the United Kingdom, USA, Germany, Austria, Italy, Spain, Portugal, and Russia.